Ajanta Pharma announced a 20% increase in Profit After Tax (PAT) for Q2 FY26. The company’s revenue from operations rose by 14% to ₹1,354 cr. The Board has approved an interim dividend of ₹28 per share. The India branded generics business continues to outperform the market. An earnings conference call will be held on November 3, 2025.
Strong Financial Performance
Ajanta Pharma reported a 20% increase in Profit After Tax (PAT) for the second quarter of fiscal year 2026. Revenue from operations reached ₹1,354 cr, a 14% increase. EBITDA stood at ₹328 cr. Excluding forex losses, EBITDA would be ₹369 cr with a margin of 27%. PAT margin reached 22%. The company’s results for Q2 (July-September) and H1 (April-September) of FY26 demonstrate strong growth and profitability.
Interim Dividend
The Board of Directors has approved an interim dividend of ₹28 per share, amounting to ₹350 cr. The record date for payment of the dividend is November 10, 2025, and payment will be made on or after November 20, 2025.
Segment Performance
Branded generics in India saw 12% growth, Asia 5% growth, and Africa 4%. US generics increased by 48%, while the Africa institution business declined by -25%.
H1 FY26 Highlights
For the first half of FY26, revenue from operations was ₹2,656 cr, up 14%. EBITDA was ₹679 cr. Excluding forex losses, EBITDA would be ₹745 cr with a margin of 28%. Profit after tax was ₹516 cr. The company is focused on branded generics in India, Asia, and Africa, with a growing US generics business and a presence in Africa’s institutional market.
Earnings Call Information
Ajanta Pharma will host an earnings conference call on November 3, 2025, at 15:00 hrs IST. The leadership team will discuss the financial performance and answer questions. Dial-in information is available on the company website.
Source: BSE
